KCAS will be represented at the International Society for Advancement of Cytometry’s upcoming CYTO meeting in Montreal, Quebec by two poster presentations being given by our talented scientists from FlowMetric.
Both posters were created in collaboration with other scientific organizations, and will focus on topics we believe the audience there will find both illuminating and valuable. We invite you to attend our presentations during the event, and to ask any questions you have of the presenters below leading up to the meeting.
Sensitivity and Stability of Quantitative Flow Cytometry Assay for Monitoring Pharmacokinetics and Pharmacodynamics of an Allogenic Cell Therapy Product in Clinical Trials
Nassouh Mourabet, Scientist III, FlowMetric
(poster made with Century Therapeutics)
Intro/Summary:
Allogenic NK cell therapy products are a promising approach to treat B cell malignancies and have the potential to overcome some of the limitations of approved autologous CAR T cell therapies by reducing time-to-treatment and having an improved safety profile. Effective, sensitive, and accurate monitoring of cellular pharmacokinetics (PK) and pharmacodynamic (PD) biomarkers are a crucial aspect of clinical development for these products. To this end, we developed a custom flow cytometry assay to assess PK and PD of one of Century Therapeutics’ induced pluripotent stem cell (iPSC)-derived Natural Killer (iNK) cell therapy products expressing an anti-CD19 CAR. CD19-positive B cell enumeration was incorporated in this assay to determine the onset and duration of B cell aplasia, which is expected to be an important PD biomarker for this product.
“Anyone in the Cell Therapy space or Cancer Research will likely find this presentation well worth their time. It would be a game-changer for the whole industry if an allogeneic product could make it on the market.” – Nassouh Mourabet, FlowMetric
HPV16-specific CD4 and CD8 T-cell Activation and Functionality in Patients Receiving Combination PDS0101 Immunotherapy
Stephen McCarthy, Scientist III, FlowMetric
(poster made with PDS Biotechnology)
Intro/Summary:
The novel HPV-targeted immunotherapy PDS0101 is being studied in combination with pembrolizumab in a Phase 2 clinical trial (VERSATILE-002, NCT04260126) in patients with HPV16-positive head and neck cancer. In this pilot study, we used PhenomeX’s CodePlex platform to establish optimal stimulation conditions for in vitro activation with selected HPV16 peptide pools that would enable downstream single cell analysis of functional cytokine profiles of HPV-specific CD4 and CD8 T cell subpopulations. The study protocol and all amendments were approved by the appropriate ethics committee at each institution. All subjects provided written informed consent prior to enrollment
“Those with an oncology focus and who are therapeutically-minded will most likely benefit from attending this poster session, especially if they are interested in an alternate platform for flow cytometry to be able to analyze samples.” – Stephen McCarthy, FlowMetric
If you have any questions about the these presentations or any others given by KCAS, please use the form below!